Participated · Seed · Mar 2026

Surf Therapeutics is developing a patented, non-invasive ultrasound neuromodulation platform aimed at treating chronic inflammatory disorders, specifically rheumatoid arthritis. The company is clinical-stage and led by CEO Nishant Doctor. It seeks to safely bring this non-invasive therapy into the home to provide scalable relief without drugs or surgery. The firm is based in Austin, TX. The company reported it will use newly received investment capital to expand its development efforts. No revenue, user metrics, past funding rounds, or valuation figures were disclosed in the article.

Participated · Series A · Oct 2025

Houston-based Koda Health offers a cloud-based advance care planning platform that blends software and services to help health plans, providers, and health systems scale goals-aligned care. The product integrates with major systems such as Epic MyChart and Guidehealth, enabling patients to create and share advance directives while giving clinicians easy access to those preferences. More than 1 million patients nationwide now use the platform, and a peer-reviewed study with Houston Methodist ACO reported a 79 % reduction in terminal hospitalizations, a 20 % cut in inpatient length of stay, a 51 % increase in hospice utilization, and nearly $9,000 in average savings per patient. Partnerships include Cigna, Privia, and Memorial Hermann. Founded out of the Texas Medical Center’s Biodesign Fellowship in 2020, the company plans to use new capital to add goals-of-care product lines, grow its national footprint, and expand engineering, clinical strategy, and customer-success teams. Koda Health closed an oversubscribed seed round last year backed by AARP, Memorial Hermann Health System, and the Texas Medical Center Venture Fund. The firm’s rapid growth and policy shifts toward patient-centered care position it to reach millions more users while reducing costs for payers and providers.

Participated · Equity · May 2025

PATH EX is developing CycloPE®, a medical device intended to rapidly eradicate bacteria from the bloodstream in patients suffering from sepsis. The company is led by CEO Sinead Miller and is based in Houston, TX. PATH EX recently raised $5M to support its program. The financing is intended to accelerate development and future commercialization of CycloPE®. In parallel with the financing the company added Jeff Burbank to its Board of Directors. Investors in the round include IAG Capital Partners, TMC Venture Fund and Fitz Gate Ventures.

Participated · Series A · May 2025

Clarium builds Astra OS, an AI-powered healthcare supply chain resiliency platform that collects, unifies, and automates crowdsourced data from providers, suppliers, and vendors. The platform predicts supply chain disruptions using real-time weather, geopolitical, and current events data and delivers tailored recommendations for substitutions and disruption resolution. Astra OS spans workflow operations, inventory and stock management, and disruption and substitution optimization, and was developed in collaboration with major health systems. Hospitals adopting Astra OS have seen over $10 million in average cost savings, 50% faster disruption resolution, and 88% substitute approvals. Clarium plans to accelerate Astra OS development with additional apps and solutions, expand its team, and grow relationships with new health system partners. The company has expanded leadership and collaborators since its 2024 seed round and has raised $43 million to date. Clarium builds Astra OS, an AI-powered workflow platform and data ecosystem that unifies real-time supply chain data and delivers workflow applications for hospitals. The platform includes modules such as Disruption Monitor, Substitute Manager, and Card Optimizer to automate inventory management and approvals. Since integrating Astra OS, partners have identified an average of $10M+ in cost savings and productivity gains, including a 50% decrease in disruption resolution time, a 63% decrease in substitute approval time, and a 3.7x growth in clinically validated substitutes approved. Yale New Haven Health reports over 300 users across seven departments actively using the platform. The company was founded in 2020 and is headquartered in New York City. Clarium plans to expand integrations, hire across data science, engineering, sales, product, and customer success, and continue investing in generative AI and large language model technologies to augment its offerings.

Participated · Equity · Jan 2025

Alleviant Medical develops the Alleviant System, a minimally invasive, no-implant atrial shunt designed to relieve excess pressure by creating a temporary connection between the left and right atrial chambers. The procedure is one-time and leaves no permanent implant behind. The Alleviant System has received U.S. FDA Breakthrough Device designation for both major forms of heart failure. The company is running pivotal clinical programs across the full spectrum of heart failure, with ALLAY-HF evaluating patients with preserved ejection fraction (HFpEF) and on track to finalize enrollment within the next year. The new program, ALLAY-HFrEF, will investigate patients with reduced ejection fraction (HFrEF) and is planned as a prospective sham-controlled pivotal trial. Alleviant is headquartered in Austin, Texas. Alleviant Medical is developing the Alleviant System, a minimally invasive, implant-free interatrial shunt intended to decompress the left atrium and treat chronic heart failure. The company has FDA Breakthrough Device designation (2021) and received an IDE approval in November 2022 to support clinical investigation. Clinical studies to date have enrolled 38 heart failure patients, showing functional and symptomatic improvement with shunt durability confirmed through six months and sustained improvement through 12 months. Alleviant will use the new financing to fund ALLAY-HF, a global, prospective, multicenter, randomized, sham-controlled, double-blinded, adaptive pivotal trial enrolling 400–700 patients with HFpEF and HFmrEF. The trial’s composite primary endpoint analysis will be conducted at one year and is designed to demonstrate safety and effectiveness of the Alleviant System. The company is headquartered in Austin, Texas and is backed by a syndicate of institutional and strategic healthcare investors.